|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US6846839B1
(en)
|
1995-06-07 |
2005-01-25 |
Sugen, Inc. |
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
|
|
AR012634A1
(es)
*
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
SK287132B6
(sk)
*
|
1998-05-29 |
2009-12-07 |
Sugen, Inc. |
Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
|
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
|
EP1162974A1
(en)
*
|
1999-03-19 |
2001-12-19 |
Parker Hughes Institute |
Quinazoline formulations and therapeutic use thereof
|
|
PT1169054E
(pt)
*
|
1999-04-09 |
2004-11-30 |
Max Planck Gesellschaft |
Produtos e metodos para tratar doencas relacionadas com ptp lar
|
|
CN1360582A
(zh)
*
|
1999-07-07 |
2002-07-24 |
阿斯特拉曾尼卡英国有限公司 |
喹唑啉衍生物
|
|
GB9925127D0
(en)
*
|
1999-10-22 |
1999-12-22 |
Pharmacia & Upjohn Spa |
Oral formulations for anti-tumor compounds
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
JP2003535038A
(ja)
*
|
1999-12-30 |
2003-11-25 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
|
|
JP3663382B2
(ja)
|
2000-02-15 |
2005-06-22 |
スージェン・インコーポレーテッド |
ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
|
|
AU2001235804A1
(en)
|
2000-03-06 |
2001-09-17 |
Astrazeneca Ab |
Therapy
|
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
|
JP2003535847A
(ja)
|
2000-06-02 |
2003-12-02 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
|
|
WO2002000644A1
(en)
|
2000-06-24 |
2002-01-03 |
Astrazeneca Ab |
Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
|
|
AU2002216758A1
(en)
*
|
2000-07-03 |
2002-01-14 |
Astrazeneca Ab |
Quinazolines with therapeutic use
|
|
CA2410683A1
(en)
*
|
2000-07-24 |
2002-01-31 |
Pharmacia & Upjohn Company |
Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
|
|
KR20030024849A
(ko)
*
|
2000-08-10 |
2003-03-26 |
델시스 파머수티컬 코포레이션 |
소수성 약물의 개선된 고형 약제학적 투여 제제
|
|
WO2002030466A2
(en)
*
|
2000-10-11 |
2002-04-18 |
Purdue Research Foundation |
Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
|
|
US20050158271A1
(en)
*
|
2000-10-11 |
2005-07-21 |
Lee Sang C. |
Pharmaceutical applications of hydrotropic polymer micelles
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
AU2002244865A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical composition of ibuprofen
|
|
US6912582B2
(en)
|
2001-03-30 |
2005-06-28 |
Microsoft Corporation |
Service routing and web integration in a distributed multi-site user authentication system
|
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
|
US6720002B2
(en)
*
|
2001-07-20 |
2004-04-13 |
R.P. Scherer Technologies, Inc. |
Antihistamine formulations for soft capsule dosage forms
|
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
|
WO2003045307A2
(en)
*
|
2001-11-21 |
2003-06-05 |
Sugen, Inc. |
Pharmaceutical formulations comprising indolinone derivatives
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
|
HUP0500200A2
(hu)
*
|
2002-01-17 |
2005-07-28 |
Neurogen Corporation |
Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
|
|
US7119209B2
(en)
*
|
2002-02-15 |
2006-10-10 |
Pharmacia & Upjohn Company |
Process for preparing indolinone derivatives
|
|
BRPI0307786B8
(pt)
*
|
2002-02-26 |
2021-05-25 |
Astrazeneca Ab |
composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
|
|
WO2003082272A1
(en)
*
|
2002-03-29 |
2003-10-09 |
Chiron Corporation |
Substituted benzazoles and use thereof as raf kinase inhibitors
|
|
US8299108B2
(en)
*
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
MXPA04010539A
(es)
|
2002-04-26 |
2005-01-25 |
Nippon Shinyaku Co Ltd |
Derivados de quinazolina y medicamentos que los contienen.
|
|
EP1569925A1
(en)
*
|
2002-12-13 |
2005-09-07 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
ITRM20030074A1
(it)
*
|
2003-02-21 |
2004-08-22 |
Pharmacia Italia Spa |
Formulazioni semisolide a rilascio immediato intese
|
|
WO2004087153A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
CA2520785A1
(en)
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Substituted 7-aza-quinazoline compounds
|
|
JP2006523638A
(ja)
|
2003-04-16 |
2006-10-19 |
エフ．ホフマン−ラ ロシュ アーゲー |
キナゾリン化合物
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
ATE395346T1
(de)
|
2003-09-16 |
2008-05-15 |
Astrazeneca Ab |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
|
KR20060118472A
(ko)
*
|
2003-10-16 |
2006-11-23 |
카이론 코포레이션 |
치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7491263B2
(en)
|
2004-04-05 |
2009-02-17 |
Technology Innovation, Llc |
Storage assembly
|
|
KR20080095915A
(ko)
|
2004-05-06 |
2008-10-29 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
|
EP3121176A1
(en)
*
|
2004-06-08 |
2017-01-25 |
Families of Spinal Muscular Atrophy |
2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
|
|
WO2006050843A1
(en)
*
|
2004-11-09 |
2006-05-18 |
F. Hoffmann-La Roche Ag |
Aminoquinazolines compounds
|
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
ES2573539T3
(es)
*
|
2005-03-21 |
2016-06-08 |
Teva Czech Industries S.R.O. |
Inhibidor de la cristalización y su uso en cápsulas de gelatina
|
|
ATE488513T1
(de)
|
2005-09-20 |
2010-12-15 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
|
PL1971338T3
(pl)
*
|
2005-12-22 |
2011-07-29 |
Astrazeneca Ab |
Połączenie ZD6474 i premetreksedu
|
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
|
US20070287707A1
(en)
*
|
2006-02-28 |
2007-12-13 |
Arrington Mark P |
Phosphodiesterase 10 inhibitors
|
|
EP2615086A1
(en)
|
2006-08-01 |
2013-07-17 |
Families of Spinal Muscular Atrophy |
2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
|
EP2200613B1
(en)
|
2007-09-21 |
2018-09-05 |
The Johns Hopkins University |
Phenazine derivatives and uses thereof
|
|
US8497369B2
(en)
|
2008-02-07 |
2013-07-30 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
|
|
CA2718416C
(en)
*
|
2008-03-13 |
2018-01-02 |
Mallinckrodt Inc. |
Multi-function, foot-activated controller for imaging system
|
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
|
|
EP2313397B1
(de)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
|
JP5359333B2
(ja)
*
|
2009-02-05 |
2013-12-04 |
ゼリア新薬工業株式会社 |
コロソリン酸含有水性液剤
|
|
MY159327A
(en)
*
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
EA021113B1
(ru)
|
2009-09-03 |
2015-04-30 |
Бристол-Майерс Сквибб Кампани |
Хиназолины в качестве ингибиторов калиевых каналов
|
|
EP2498753B1
(en)
*
|
2009-11-10 |
2019-03-06 |
Celgene Corporation |
Nanosuspension of a poorly soluble drug made by microfluidization process
|
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
|
CN102716103B
(zh)
*
|
2012-07-02 |
2013-12-18 |
西安力邦制药有限公司 |
2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
CN103837615B
(zh)
*
|
2014-02-15 |
2015-05-20 |
青岛农业大学 |
一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法
|
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
US20160361322A1
(en)
|
2015-06-15 |
2016-12-15 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
|
AU2017329090B9
(en)
|
2016-09-19 |
2019-09-05 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
|
|
US11559530B2
(en)
|
2016-11-28 |
2023-01-24 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
|
CA3057969A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
WO2020018974A1
(en)
|
2018-07-20 |
2020-01-23 |
Lipocine Inc. |
Liver disease
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
EP4138783A4
(en)
*
|
2020-04-22 |
2024-04-10 |
Scienture, Inc. |
Long-acting bupivacaine microsphere formulations
|
|
CN113398067B
(zh)
*
|
2021-07-19 |
2022-08-16 |
宁波三生生物科技股份有限公司 |
一种四烯雌酮注射液及其制备方法和应用
|